The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
Primary Purpose
Glioma, Astrocytoma, Oligodendroglioma
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Temozolomide
Sponsored by
About this trial
This is an interventional treatment trial for Glioma
Eligibility Criteria
Inclusion Criteria:
- Adult patients, greater than 18 years old.
- Surgically confirmed diagnosis of malignant glioma, specifically anaplastic glioma (anaplastic astrocytoma [AA], anaplastic oligodendroglioma [AO], anaplastic oligoastrocytoma [AOA]) or glioblastoma multiforme (GBM).
- Must have completed at least 2 cycles (2 months) of conventional 5/28 temozolomide, with radiological evidence of progression.
- GBM treated with concurrent chemoradiation with temozolomide according to the EORTC/NCIC (European Organization for Research & Treatment of Cancer/National Cancer Institute of Canada) protocol.
- Evidence of progression confirmed radiologically (CT [computed tomography] or MRI [magnetic resonance imaging]).
- Patients must be enrolled within 2 weeks of last radiological confirmation of progression, except for patients undergoing surgical resection.
- Patients undergoing surgical resection for recurrent disease must be enrolled within 2 weeks of the post-surgical scan.
- Patients with no residual disease after surgery are allowed.
- Steroids dose should have been stabilized during the last 2 weeks prior to enrollment.
- Use of medically approved contraception in fertile males and females.
- Women of childbearing potential must have a negative urine or serum pregnancy test (urinary excretion or serum level of bHCG [beta human chorionic gonadotropin]) within 24 hours of inclusion in the study.
- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
- Signed informed consent form.
Exclusion Criteria:
- GBM progression during the first 2 months of adjuvant temozolomide (5/28).
- AA progression during the first 2 months of standard temozolomide therapy (5/28).
- Chemotherapy for the malignant glioma other than temozolomide.
- More than one prior course of chemotherapy with temozolomide.
- Patient evolving from anaplastic glioma to GBM following primary therapy.
- Patient older than 70 years or who received no conventional chemoradiation regimen.
- Patient who received radiotherapy for recurrent disease.
- Patient with metastatic disease.
- Known human immunodeficiency virus (HIV) infection.
- History of non-compliance to other therapies.
- Inadequate hematological, renal and hepatic function according to all of the following laboratory values (to be performed within 14 days, inclusive, prior to study inclusion):
- Absolute neutrophil count <=1.5 ×10^9/L;
- Platelets <=100 ×10^9/L;
- Hemoglobin <90 g/L;
- Serum creatinine >=1.5 times upper limit of laboratory normal (ULN);
- Total serum bilirubin >=1.5 times ULN;
- ASAT (AST [aspartate aminotransferase]) or ALAT (ALT [alanine aminotransferase) >2.0 times ULN;
- Alkaline phosphatase of >2.5 times ULN.
- Known chronic hepatitis B or hepatitis C infection.
- Any other serious medical condition, according to the medical judgment of the physician prior to inclusion in the study.
- Any medical condition that could interfere with oral medication intake (e.g., frequent vomiting, partial bowel obstruction).
- Other malignancies during the previous 5 years with the exception of surgically cured carcinoma in-situ of the cervix and basal cell carcinoma or non-melanoma skin cancer.
- Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule as discussed with the patient before inclusion in the study.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Temozolomide
Arm Description
Temozolomide will be administered at a dose of 50 mg/m^2 for cycles of 28 days for 12 months or until progression.
Outcomes
Primary Outcome Measures
Percentage of Participants Surviving at Six Months of Treatment Without Evidence of Disease Progression.
Progression-free survival as determined by Kaplan-Meier method.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00392171
Brief Title
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
Official Title
The Temozolomide RESCUE Study: A Phase II Trial of Continuous (28/28) Dose-intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28 Day Temozolomide in Patients With Recurrent Malignant Glioma
Study Type
Interventional
2. Study Status
Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
June 9, 2006 (Actual)
Primary Completion Date
September 15, 2009 (Actual)
Study Completion Date
September 15, 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
4. Oversight
5. Study Description
Brief Summary
The purpose of this non-randomized, open-label, multicenter, Phase II, 2-stage design, RESCUE study is to test the hypothesis that continuous 28-day oral dosing (28/28) with dose-intense temozolomide (50 mg/m^2) for up to 12 months may overcome resistance and be effective in the management of adult patients with malignant glioma who have failed following at least 2 cycles (2 months) of conventional 5-day (5/28) cycles of high-dose temozolomide (150-200 mg/m^2).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glioma, Astrocytoma, Oligodendroglioma, Glioblastoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Temozolomide
Arm Type
Experimental
Arm Description
Temozolomide will be administered at a dose of 50 mg/m^2 for cycles of 28 days for 12 months or until progression.
Intervention Type
Drug
Intervention Name(s)
Temozolomide
Other Intervention Name(s)
SCH 52365
Intervention Description
Subjects will receive temozolomide 50 mg/m^2 for cycles of 28 days for 12 months or until progression
Primary Outcome Measure Information:
Title
Percentage of Participants Surviving at Six Months of Treatment Without Evidence of Disease Progression.
Description
Progression-free survival as determined by Kaplan-Meier method.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult patients, greater than 18 years old.
Surgically confirmed diagnosis of malignant glioma, specifically anaplastic glioma (anaplastic astrocytoma [AA], anaplastic oligodendroglioma [AO], anaplastic oligoastrocytoma [AOA]) or glioblastoma multiforme (GBM).
Must have completed at least 2 cycles (2 months) of conventional 5/28 temozolomide, with radiological evidence of progression.
GBM treated with concurrent chemoradiation with temozolomide according to the EORTC/NCIC (European Organization for Research & Treatment of Cancer/National Cancer Institute of Canada) protocol.
Evidence of progression confirmed radiologically (CT [computed tomography] or MRI [magnetic resonance imaging]).
Patients must be enrolled within 2 weeks of last radiological confirmation of progression, except for patients undergoing surgical resection.
Patients undergoing surgical resection for recurrent disease must be enrolled within 2 weeks of the post-surgical scan.
Patients with no residual disease after surgery are allowed.
Steroids dose should have been stabilized during the last 2 weeks prior to enrollment.
Use of medically approved contraception in fertile males and females.
Women of childbearing potential must have a negative urine or serum pregnancy test (urinary excretion or serum level of bHCG [beta human chorionic gonadotropin]) within 24 hours of inclusion in the study.
Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
Signed informed consent form.
Exclusion Criteria:
GBM progression during the first 2 months of adjuvant temozolomide (5/28).
AA progression during the first 2 months of standard temozolomide therapy (5/28).
Chemotherapy for the malignant glioma other than temozolomide.
More than one prior course of chemotherapy with temozolomide.
Patient evolving from anaplastic glioma to GBM following primary therapy.
Patient older than 70 years or who received no conventional chemoradiation regimen.
Patient who received radiotherapy for recurrent disease.
Patient with metastatic disease.
Known human immunodeficiency virus (HIV) infection.
History of non-compliance to other therapies.
Inadequate hematological, renal and hepatic function according to all of the following laboratory values (to be performed within 14 days, inclusive, prior to study inclusion):
Absolute neutrophil count <=1.5 ×10^9/L;
Platelets <=100 ×10^9/L;
Hemoglobin <90 g/L;
Serum creatinine >=1.5 times upper limit of laboratory normal (ULN);
Total serum bilirubin >=1.5 times ULN;
ASAT (AST [aspartate aminotransferase]) or ALAT (ALT [alanine aminotransferase) >2.0 times ULN;
Alkaline phosphatase of >2.5 times ULN.
Known chronic hepatitis B or hepatitis C infection.
Any other serious medical condition, according to the medical judgment of the physician prior to inclusion in the study.
Any medical condition that could interfere with oral medication intake (e.g., frequent vomiting, partial bowel obstruction).
Other malignancies during the previous 5 years with the exception of surgically cured carcinoma in-situ of the cervix and basal cell carcinoma or non-melanoma skin cancer.
Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule as discussed with the patient before inclusion in the study.
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
Citations:
PubMed Identifier
20308655
Citation
Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 Apr 20;28(12):2051-7. doi: 10.1200/JCO.2009.26.5520. Epub 2010 Mar 22. Erratum In: J Clin Oncol. 2010 Jul 20;28(21):3543.
Results Reference
result
Learn more about this trial
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
We'll reach out to this number within 24 hrs